Turner Claire E, Kurupati Prathiba, Wiles Siouxsie, Edwards Robert J, Sriskandan Shiranee
Department of Infectious Diseases & Immunity, Hammersmith Hospital, Du Cane Road, London, W12 0NN, United Kingdom.
Vaccine. 2009 Aug 6;27(36):4923-9. doi: 10.1016/j.vaccine.2009.06.042. Epub 2009 Jun 27.
Currently there is no licensed vaccine against the human pathogen Streptococcus pyogenes. The highly conserved IL-8 cleaving S. pyogenes cell envelope proteinase SpyCEP is surface expressed and is a potential vaccine candidate. A recombinant N-terminal part of SpyCEP (CEP) was expressed and purified. AntiCEP antibodies were found to neutralize the IL-8 cleaving activity of SpyCEP. CEP-immunized mice had reduced bacterial dissemination from focal S. pyogenes intramuscular infection and intranasal infection. We also identified a functional SpyCEP-homolog protease SeCEP, expressed by the equine pathogen Streptococcus equi, which was able to cleave both human and equine IL-8. CEP-immunized mice also demonstrated reduced bacterial dissemination from S. equi intramuscular infection. Therefore immunization against SpyCEP may provide protection against other streptococci species with homologous proteases.
目前尚无针对人类病原体化脓性链球菌的许可疫苗。高度保守的切割白细胞介素-8(IL-8)的化脓性链球菌细胞包膜蛋白酶SpyCEP在表面表达,是一种潜在的疫苗候选物。表达并纯化了SpyCEP的重组N端部分(CEP)。发现抗CEP抗体可中和SpyCEP的IL-8切割活性。用CEP免疫的小鼠中,来自局部化脓性链球菌肌肉感染和鼻内感染的细菌播散减少。我们还鉴定了一种功能性SpyCEP同源蛋白酶SeCEP,它由马病原体马链球菌表达,能够切割人和马的IL-8。用CEP免疫的小鼠也显示出来自马链球菌肌肉感染的细菌播散减少。因此,针对SpyCEP进行免疫接种可能为抵御具有同源蛋白酶的其他链球菌物种提供保护。